| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
Alanine glutamate targets various biological pathways involved in antioxidant defense, inflammation, and neuroprotection. As a dipeptide, it may be hydrolyzed to its constituent amino acids, alanine and glutamic acid, which are involved in numerous metabolic pathways. Alanine is a key amino acid in glucose metabolism and glutamate is a major excitatory neurotransmitter. The compound's antioxidant and anti-inflammatory effects may be mediated through its amino acid components.
|
|---|---|
| ln Vitro |
In vitro, Alanine glutamate has been shown to have antioxidant, anti-inflammatory, and neuroprotective effects. Its ability to reduce oxidative stress and inflammation has been characterized in various cell-based assays. The compound's neuroprotective effects have been demonstrated in neuronal cell cultures. Its potential therapeutic applications in Alzheimer's disease, Parkinson's disease, and cancer have been investigated.
|
| ln Vivo |
In vivo, Alanine glutamate has potential therapeutic applications in the treatment of various diseases, including Alzheimer's disease, Parkinson's disease, and cancer. As a dipeptide, it may be hydrolyzed to its constituent amino acids to exert its biological effects. Studies have examined its effects in animal models of neurodegenerative diseases and cancer. Its pharmacokinetic properties and tissue distribution have been characterized.
|
| Enzyme Assay |
In cell-free biochemical assays, Alanine glutamate is characterized for its chemical properties and purity. Its molecular weight (218.21 g/mol) and molecular formula (C8H14N2O5) are determined using analytical techniques. Its purity (>98%) is assessed by HPLC. Its antioxidant activity is assessed using standard biochemical assays measuring free radical scavenging capacity. Its stability and solubility are evaluated.
|
| Cell Assay |
Cellular assays for Alanine glutamate involve evaluating its antioxidant, anti-inflammatory, and neuroprotective effects in various cell lines. The compound's ability to reduce oxidative stress is assessed by measuring cellular oxidative stress markers. Its anti-inflammatory effects are evaluated by measuring cytokine production and inflammatory marker expression. Its neuroprotective effects are assessed in neuronal cell cultures.
|
| Animal Protocol |
Animal models for Alanine glutamate include models of neurodegenerative diseases and cancer. The compound is typically administered via injection or oral routes. Studies have examined its effects on disease progression, inflammatory markers, and oxidative stress parameters. Its pharmacokinetic properties and tissue distribution have been characterized.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Alanine glutamate show that the compound has a molecular weight of 218.21 g/mol with a molecular formula of C8H14N2O5. The CAS number is 13187-90-1. The compound has a density of 1.4±0.1 g/cm3 and a boiling point of 520.5±50.0 °C at 760 mmHg. It typically exists as a white powder at room temperature. Standard handling procedures for amino acid derivatives apply.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Alanine glutamate has not been extensively documented. As a naturally occurring dipeptide, it is considered to have a favorable safety profile. Standard safety precautions for handling laboratory chemicals apply. The compound is for research use only and not for human use.
|
| Additional Infomation |
L-Alanyl-L-glutamic acid is a dipeptide composed of L-glutamic acid with an L-alanyl group attached to its α-amino group. L-Alanyl-L-glutamic acid is a metabolite found or produced in Escherichia coli (K12 strain, MG1655 strain).
Alanine glutamate (L-Alanyl-L-Glutamic Acid) is a dipeptide with antioxidant, anti-inflammatory, and neuroprotective effects. It has potential therapeutic applications in Alzheimer's disease, Parkinson's disease, and cancer. The compound has a molecular weight of 218.21 g/mol and formula C8H14N2O5. The CAS number is 13187-90-1. |
| Exact Mass |
218.09
|
|---|---|
| CAS # |
13187-90-1
|
| PubChem CID |
128841
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
520.5±50.0 °C at 760 mmHg
|
| Flash Point |
268.6±30.1 °C
|
| Vapour Pressure |
0.0±2.9 mmHg at 25°C
|
| Index of Refraction |
1.528
|
| LogP |
-2.33
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
15
|
| Complexity |
266
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)N
|
| InChi Key |
VYZAGTDAHUIRQA-WHFBIAKZSA-N
|
| InChi Code |
InChI=1S/C8H14N2O5/c1-4(9)7(13)10-5(8(14)15)2-3-6(11)12/h4-5H,2-3,9H2,1H3,(H,10,13)(H,11,12)(H,14,15)/t4-,5-/m0/s1
|
| Chemical Name |
(2S)-2-[[(2S)-2-aminopropanoyl]amino]pentanedioic acid
|
| Synonyms |
Alanine glutamate L-Glutamic acid, N-L-alanyl- Alanylglutamic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~250 mg/mL (~1145.69 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (458.27 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT03493178 | RECRUITING | Dietary Supplement: Glycine Dietary Supplement: N-acetylcysteine (NAC) Dietary Supplement: Alanine |
Mild Cognitive Impairment | Baylor College of Medicine | 2018-04-14 | Early Phase 1 |
| NCT03180775 | UNKNOWN STATUS | Other: Cellulose (control) Dietary Supplement: Glycine Dietary Supplement: Alanine |
Atherosclerosis Diet Modification Serum; Disease |
Rambam Health Care Campus | 2017-07-01 | Not Applicable |
| NCT00005767 | UNKNOWN STATUS | Kidney Diseases | National Center for Research Resources (NCRR) | |||
| NCT01048905 | COMPLETEDWITH RESULTS | Drug: L-Glutamine | Pulmonary Hypertension Sickle Cell Disease Thalassemia |
UCSF Benioff Children's Hospital Oakland | 2009-03 | Phase 2 |
| NCT06059911 | ACTIVE, NOT RECRUITING | Dietary Supplement: Multi-ingredient dietary supplement (caffeine, creatine monohydrate, β-alanine, citrulline malate, BCAA) Dietary Supplement: Placebo dietary supplement (97% maltodextrin) |
Sport Performance | Athanasios Z. Jamurtas | 2022-06-15 | Not Applicable |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
